24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
OXALIEVA 50MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | OXALIEVA 50MG |
|---|---|
| Composition | Oxaliplatin Injection USP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
OXALIEVA 50MG (Oxaliplatin Injection USP 50mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
OXALIEVA 50 MG (Oxaliplatin Injection USP 50 mg) is a prescription anticancer medicine containing Oxaliplatin 50 mg, a platinum-based chemotherapy agent widely used in the treatment of colorectal cancer and certain other gastrointestinal malignancies. Oxaliplatin belongs to the class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells and preventing them from growing and multiplying.
Cancer cells divide rapidly and require healthy DNA to survive and spread. Oxaliplatin forms cross-links within DNA strands, disrupting the genetic material of cancer cells and ultimately causing cancer cell death. This action helps slow tumor progression and supports effective disease management.
OXALIEVA 50 MG is commonly administered as part of combination chemotherapy regimens such as FOLFOX (Oxaliplatin, Leucovorin, and 5-Fluorouracil), which is widely used in the treatment of colon and rectal cancers. The 50 mg strength allows healthcare professionals to tailor treatment doses according to individual patient requirements and treatment protocols.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
OXALIEVA 50 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, OXALIEVA 50 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Oxaliplatin therapy require regular blood tests, liver and kidney function monitoring, and neurological evaluations to ensure safe and effective treatment.
Due to its proven efficacy in colorectal cancer treatment, OXALIEVA 50 MG remains an important component of modern oncology care.
OXALIEVA 50 MG (Oxaliplatin Injection USP 50 mg) is primarily used in the treatment and management of specific cancers.
The medicine is widely used for the treatment of colon and rectal cancers.
Oxaliplatin helps manage advanced cancer that has spread to other parts of the body.
The medicine may be administered after surgery to help reduce the risk of cancer recurrence.
Doctors may include Oxaliplatin in treatment plans for selected gastrointestinal malignancies.
The medicine is commonly used alongside fluoropyrimidine-based therapies.
Oxaliplatin helps slow disease progression and improve treatment outcomes.
The medicine is incorporated into internationally recognized chemotherapy regimens.
Oxaliplatin belongs to a class of medicines known as Platinum-Based Anticancer Agents.
OXALIEVA works by:
This mechanism helps control cancer progression and supports effective treatment outcomes.
Like all medicines, OXALIEVA 50 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Numbness, tingling, or nerve sensitivity in the hands and feet is commonly reported.
Patients may experience discomfort when exposed to cold temperatures or cold objects.
Digestive disturbances may occur during treatment.
Weakness and tiredness are frequently reported.
Digestive discomfort may occur.
Reduced appetite may affect nutritional intake.
The medicine may decrease white blood cells, red blood cells, and platelet counts.
Inflammation or ulcers inside the mouth may develop.
Lower white blood cell counts may increase susceptibility to infections.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of OXALIEVA 50 MG (Oxaliplatin Injection USP 50 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the disease being treated.
Dosage is typically calculated according to body surface area.
The chemotherapy regimen influences dosing schedules.
Regular laboratory monitoring helps guide treatment decisions.
Kidney, liver, and bone marrow function may affect dosage planning.
Before starting treatment, inform your doctor if you have:
Patients receiving Oxaliplatin should:
Patients should also disclose all prescription medicines, vitamins, supplements, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of colorectal cancer and selected gastrointestinal cancers.
Oxaliplatin is a platinum-based chemotherapy medicine that damages cancer cell DNA and prevents tumor growth.
Yes. Oxaliplatin is a platinum-based chemotherapy agent.
Peripheral neuropathy, including numbness and tingling in the hands and feet, is one of the most common side effects.
The medicine can affect nerves, causing temporary sensitivity to cold temperatures and cold objects.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Blood tests, neurological evaluations, and clinical assessments are important throughout therapy.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.